[ad_1]
Aspen Group CEO Stephen Saad said this project will receive priority.
“We have invested globally in our sterile capacity and are determined to play a role in vaccine manufacturing to add to our proud history of making contributions to humanity in times of global pandemics,” he said.
“This has included, Among others, being a leading global provider of antiretrovirals for the treatment of HIV / AIDS, products for multidrug-resistant tuberculosis and treatments related to Covid-19, such as anesthetics and dexamethasone.
“Johnson & Johnson selected us as a vaccine partner and this project will receive a priority focus. We are particularly pleased to have the opportunity to provide care to patients in need around the world from our SoA base. ”
According to Reuters, Johnson & Johnson said it plans to start testing its experimental Covid-19 vaccine in children between the ages of 12 and 18 as soon as possible.
The company’s Dr. Jerry Sadoff said that depending on safety and other factors, he also plans to test even younger children afterward.
Johnson & Johnson announced in September that it was testing the vaccine in adults as part of a phase 3 study of 60,000 volunteers. He stopped the trial last month due to “unexplained illness in a study participant” but resumed it two weeks later.
TimesLIVE
[ad_2]
